News | Image Guided Radiation Therapy (IGRT) | August 21, 2017

Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System

Freestanding center is first in the western U.S. to treat patients with this "smart" radiation therapy delivery system with fully integrated treatment planning and data management systems

Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System

August 21, 2017 — Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact Treatment Delivery System, the next-generation TomoTherapy platform. The Radixact System replaced a competitive conventional linear accelerator in the single-vault freestanding facility.

The system provides precise and accurate treatments for more routine radiation therapy indications including skin, central nervous system, breast, head and neck, lung, prostate, gynecologic and gastrointestinal malignancies, in addition to more complex treatments such as craniospinal and total marrow irradiation. Additionally, Summit Cancer Center-Boise has the ability to perform stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT).

"At Summit Cancer Center-Boise our goal is to use innovative technology to provide our patients with the treatment best suited to their needs. This system allows us to provide precise, individualized treatment while sparing normal tissues and maintaining optimal treatment efficacy," said John E. Gamboa, M.D., radiation oncologist, medical director of Summit Cancer Center-Boise.

The use of radiation as part of cancer treatment is increasing, both during initial treatment and increasingly for re-treatment, so the ability to deliver the correct dose precisely to the tumor is becoming even more important. The Radixact System was designed to deliver image-guided intensity-modulated radiation therapy, an extremely precise form of radiation therapy.

  • The system is built on a ring gantry platform with a computed tomography (CT) scanner. It provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles, ensuring the most precise treatment customized for each patient, minimizing exposure to healthy tissue and measurably mitigating side effects;
  • Treatment accuracy is achieved through daily 3-D image guidance, which ensures proper patient positioning and dose targeting even when anatomical changes occur. The system takes an image of the patient every day as part of the patient setup, enabling the clinical team to know exactly where the tumor is on that particular day;
  • The ultra-fast binary multileaf collimator (MLC) is a key component of the system, enabling it to deliver dose with extremely high precision and accuracy;
  • Continuous couch motion through the bore of the ring gantry facilitates seamless delivery to multiple targets or long volumes with no need for field matching, which would be required if using a conventional delivery device. This innovation in workflow also improves treatment quality by ensuring that highly-sculpted radiation doses can be delivered to tumors located anywhere in the body, regardless of the tumor size or the number of tumors receiving treatment;
  • A fully-integrated, simplified adaptive treatment planning solution, PreciseART Adaptive Radiation Therapy software, enables the clinical team to adjust therapy to changes in tumor size, shape and location — as well as subtle changes in the location of organs and other healthy tissue; and
  • The PreciseRTX Retreatment Option makes it easier for clinicians to deliver precise doses of radiation in those cases where, unfortunately, cancer has recurred and retreatment with radiation is necessary.

For more information: www.accuray.com

Related Content

Vinai Gondi, M.D., the Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

Vinai Gondi, M.D., Director of Research at the Northwestern Medicine Chicago Proton Center, Co-director of the Brain Tumor Center at Northwestern Medicine Cancer Center, Warrenville, and lead author of the NRG-BN001 abstract.

News | Intensity Modulated Radiation Therapy (IMRT) | October 27, 2020
October 27, 2020 — A...
"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial" was presented by Jing Li, M.D., The University of Texas MD Anderson Cancer Center, at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — Results of a new randomized phase III trial suggest that...
"Stereotactic ablative fractionated radiotherapy versus radiosurgery for oligometastatic neoplasia to the lung: A randomised phase II trial," presented by Shankar Siva, Ph.D., Peter MacCallum Cancer Centre, was presented at ASTRO20
News | Stereotactic Body Radiation Therapy (SBRT) | October 26, 2020
October 26, 2020 — A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the cas
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...
A randomized phase II/III study comparing 24Gy in 2 stereotactic body radiotherapy (SBRT) fractions versus 20Gy in 5 conventional palliative radiotherapy (CRT) fractions for patients with painful spinal metastases was presented by Arjun Sahgal, M.D., University of Toronto, today at ASTRO20
News | Radiation Therapy | October 26, 2020
October 26, 2020 — A new study shows using fewer and higher doses of high-precision...
Nearly 40 MRIdian-focused presentations will be part of the ASTRO Scientific Sessions
News | Magnetic Resonance Imaging (MRI) | October 26, 2020
October 26, 2020 — ViewRay, Inc. announced that the company's MRIdian Linac MRI-guided radiation therapy system will
Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.
News | Proton Therapy | October 25, 2020
October 25, 2020 — Treating lung cancer patients with prot...
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...